Solid Biosciences received FDA approval for a gene therapy trial on July 9, 2025.
2 reports, 1 independent
Updated Sep 2
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Solid Biosciences received FDA approval for a gene therapy trial on July 9, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA cleared an IND application for a gene therapy being researched at Massachusetts General Hospital.1 source
- Solid Biosciences gets FDA approval for gene therapy trial.
Keep exploring
The entities involved
- FDA
-
Massachusetts General Hospital
teaching hospital in Boston, Massachusetts, United States
- Peter Grinspoon and Kevin Hill have taken on new instructor and professor roles at Massachusetts General Hospital, Harvard Medical School, and Beth Israel Deaconess Medical Center.
- Mass General Brigham is facing financial problems, leading to mergers with MGH and patient transfers within Massachusetts.
Related events
- uniQure N.V. traded on the Nasdaq stock exchange and submitted a Biologics License Application (BLA) for accelerated approval of its gene therapy.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- Research advances have led to the approval of new therapies by the FDA.
- A network focused on cell and gene therapies is expanding to include sites in Northern California, involving the CA Institute for Regenerative Medicine and the FDA.
- CRISPR Therapeutics and Vertex Pharmaceuticals received FDA approval for their gene therapy Casgevy for sickle cell disease.
Coverage
Newest first; wire copies grouped- prnewswire.com
- Unknown outlet